Edition:
United Kingdom

Illumina Inc (ILMN.OQ)

ILMN.OQ on NASDAQ Stock Exchange Global Select Market

334.62USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$334.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
361,171
52-wk High
$372.46
52-wk Low
$207.94

Summary

Name Age Since Current Position

Jay Flatley

65 2016 Executive Chairman of the Board

Francis deSouza

47 2016 President, Chief Executive Officer, Director

Sam Samad

48 2016 Chief Financial Officer, Senior Vice President

Garret Hampton

52 2017 Executive Vice President - Clinical Genomics

Omead Ostadan

46 2017 Executive Vice President, Operations and Products

Marc Stapley

48 2017 Executive Vice President, Strategy and Corporate Development

Mostafa Ronaghi

49 2008 Chief Technology Officer, Senior Vice President

Charles Dadswell

59 2013 Senior Vice President, General Counsel, Secretary

Aimee Hoyt

47 2018 Senior Vice President and Chief People Officer

Mark Van Oene

45 2017 Senior Vice President, Chief Commercial Officer

Phillip Febbo

51 2018 Chief Medical Officer

Frances Arnold

61 2016 Independent Director

Caroline Dorsa

58 2017 Independent Director

Karin Eastham

68 2004 Independent Director

Robert Epstein

63 2012 Independent Director

Gary Guthart

52 2017 Independent Director

Philip Schiller

57 2017 Independent Director

John Thompson

68 2017 Independent Director

Jacquie Ross

2017 Vice President, Investor Relations

Biographies

Name Description

Jay Flatley

Mr. Jay T. Flatley is an Executive Chairman of the Board of Illumina, Inc, effective July 5, 2016. He was Chief Executive Officer, Director of Illumina, Inc. Prior to joining Illumina, Mr. Flatley was co-founder, President, Chief Executive Officer, and a director of Molecular Dynamics, Inc., a NASDAQ-listed life sciences company focused on genetic discovery and analysis, from 1994 until its sale to Amersham Pharmacia Biotech Inc. in 1998. He served in various other positions of increasing responsibility with Molecular Dynamics from 1987 to 1994. From 1985 to 1987, Mr. Flatley was Vice President of Engineering and Vice President of Strategic Planning at Plexus Computers, a UNIX computer company. Mr. Flatley also serves as a director of Coherent, Inc. a NASDAQ-listed provider of photonics-based solutions to commercial and scientific research markets. Mr. Flatley holds a B.A. in Economics from Claremont McKenna College and a B.S. and M.S. in Industrial Engineering from Stanford University.

Francis deSouza

Mr. Francis A. deSouza is the President, Chief Executive Officer, Director of Illumina Inc. Mr. deSouza has served as President since December 2013 and as a Director since January 2014. Prior to joining Illumina, Mr. deSouza was President, Products and Services, of Symantec Corporation, a NASDAQ-listed software technology company, from 2011 to 2013, and Mr. deSouza served as Symantec’s Senior Vice President, Enterprise Security Group, from 2009 to 2011. Prior to joining Symantec, from 2001 to 2006, he was Founder and Chief Executive Officer of IMlogic, Inc. an enterprise instant messaging software company that was acquired by Symantec in 2006, and Mr. deSouza served as a Product Unit Manager, Real-time Collaboration Group, at Microsoft Corporation from 1998 to 2001. Prior to joining Microsoft, from 1997 to 1998, Mr. deSouza was co-founder and Chief Executive Officer of Flash Communications, an enterprise instant messaging company that was acquired by Microsoft in 1998. Mr. deSouza is Chairman of the board of directors of MedHelp International, a privately-held online health community. Mr. deSouza received a bachelor’s degree in electrical engineering and computer science with a minor in economics and a master’s degree from Massachusetts Institute of Technology.

Sam Samad

Mr. Sam A. Samad is the Chief Financial Officer, Senior Vice President of Illumina, Inc. Mr. Samad, most recently served as Senior Vice President and Corporate Treasurer at Cardinal Health from 2012 to 2016 where, in addition to treasury, he also had leadership responsibility for Cardinal Health’s China business. From 2009 to 2012 he served as Senior Vice President and CFO of Cardinal Health’s Pharmaceutical Segment, and from 2007 to 2009 he served as Vice President, Finance of Cardinal Health’s Supply Chain Services. Prior to joining Cardinal Health in 2007, Mr. Samad held finance roles at Eli Lilly and Pepsico Inc. Mr. Samad holds a BBA degree from American University of Beirut in Lebanon and an MBA from McMaster University in Hamilton, Canada.

Garret Hampton

Mr. Garret Hampton, Ph.D. is an Executive Vice President - Clinical Genomics of Illumina, Inc, effective January 9, 2017. Garret will be responsible for leading the clinical genomics group, including the reproductive and genetic health and oncology businesses, regulatory, clinical and medical affairs, CLIA labs, and the Chief Medical Officer's organization. He joins Illumina from Genentech, Inc. where he was Global Head of Oncology Biomarker Development and Companion Diagnostics, co-led the Roche Personalized Medicine R&D Initiative and chaired the Roche/Foundation Medicine Joint R&D Committee. He previously held scientific and management roles at Celgene Corporation, Genomics Institute of the Novartis Research Foundation, and University of California at San Diego. Garret holds a BA in natural sciences and genetics and MA in natural sciences from Trinity College in Dublin, Ireland, and a PhD in cancer genetics from Imperial Cancer Research Fund and the University College London.

Omead Ostadan

Mr. Omead Ostadan is an Executive Vice President, Operations and Products of Illumina, Inc. Mr. Ostadan is an Executive Vice President - Operations, Products and Strategy of the company. Prior to that he served as Senior Vice President, Operations and Development. Mr. Ostadan is Senior Vice President, Product Development from 2011 to 2015.

Marc Stapley

Mr. Marc A. Stapley is no longer Executive Vice President, Strategy and Corporate Development of Illumina, Inc effective as of January 1, 2019. Mr. Stapley is an Executive Vice President, Chief Administrative Officer of Illumina, Inc. Mr. Stapley was Chief Financial Officer of the Company. Mr. Stapley joins Illumina from Pfizer where he served as Senior Vice President responsible for global financial processes and systems, integration efforts in both the Wyeth and King Pharmaceutical acquisitions and providing oversight to the company’s technology investment program. Prior to Pfizer, he served in a variety of senior finance roles at Alcatel-Lucent, including Americas CFO. He also worked as Finance Director and Controller for several groups at Cadence Design Systems. Stapley began his career as an Auditor at Coopers & Lybrand. Mr. Stapley holds a First Class BSc (Honors) in Mathematics from The University of Reading (England) and is a member of the Institute of Chartered Accountants in England and Wales.

Mostafa Ronaghi

Dr. Mostafa Ronaghi, Ph.D. is the Chief Technology Officer, Senior Vice President of Illumina, Inc. Dr. Ronaghi joined Illumina in August 2008; 2002 – 2008: principal investigator at Stanford University, where Dr. Ronaghi focused on the development of novel tools for molecular diagnostic applications; 2007 – 2008: chairman and chief scientific officer for Avantome, Inc. a privately-held sequencing company co-founded by Dr. Ronaghi and acquired by Illumina in 2008.

Charles Dadswell

Mr. Charles E. Dadswell is the Senior Vice President, General Counsel, Secretary of Illumina Inc. since April 22, 2013. Mr. Dadswell joins Illumina with more than 20 years of leadership and legal experience at health care-focused technology companies. Most recently, he was Vice President, General Counsel for North and Latin America and Corporate Director of Global Intellectual Property at bioMerieux. In this role, he was responsible for a global intellectual property matters and legal matters in North and Latin America. Prior to bioMerieux, he was General Counsel of BioDelivery Sciences International, a specialty pharmaceutical company; and oversaw US intellectual property in a variety of positions with Glaxo, GlaxoWellcome and GlaxoSmithKline. Mr. Dadswell holds a LLM in patent law and trade regulation from The George Washington University Law School, a JD from the Thomas M. Cooley Law School and a bachelor's in science from Ferris State University.

Aimee Hoyt

Ms. Aimee L. Hoyt is the Senior Vice President and Chief People Officer of Illumina, Inc, effective January 8, 2018. Ms. Hoyt has held senior positions at some of the world's best-known technology companies including Hewlett-Packard, Cisco and Sun Microsystems. Most recently, she was the Chief Human Resources Officer at Rackspace, a leading managed cloud computing company, in San Antonio, Texas. She led the HR team and was responsible for helping build, align and develop high-performing global teams. During her tenure, Rackspace was recognized as one of Fortune's 100 Best Companies to Work For, Top 30 Best Places in Tech and Great Places to Work for Millennials. Ms. Hoyt earned a master's in human resource development from the Rochester Institute of Technology.

Mark Van Oene

Mr. Mark Van Oene is the Senior Vice President, Chief Commercial Officer of Illumina, Inc. Mr. Van Oenewas previously the Company's Senior Vice President of the Americas region and subsequently named interim Chief Commercial Officer in late 2016. He will be responsible for worldwide sales, services, and marketing at the Company.

Phillip Febbo

Dr. Phillip Febbo M.D., is no longer the Chief Medical Officer of Illumina, Inc, effective March 26, 2018. For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.

Frances Arnold

Dr. Frances Arnold is an Independent Director of Illumina, Inc. Dr. Arnold manages a research group at the California Institute of Technology and is the Dick and Barbara Dickinson Professor of Chemical Engineering, Bioengineering and Biochemistry at the California Institute of Technology and Director of the Donna and Benjamin M. Rosen Bioengineering Center. She joined the California Institute of Technology in 1986 and has served as a Visiting Associate, Assistant Professor, Professor, and Director. Dr. Arnold’s laboratory focuses on protein engineering by directed evolution, with applications in alternative energy, chemicals, and medicine. She is the recipient of numerous honors, including induction into the National Inventors Hall of Fame, Fellow of the National Academy of Inventors, the ENI Prize in Renewable and Nonconventional Energy, the U.S. National Medal of Technology and Innovation, and the Charles Stark Draper Prize of the U.S. National Academy of Engineering. Dr. Arnold is an elected member of all three U.S. National Academics of Science, Medicine, and Engineering, as well as the American Academy of Arts and Sciences. Dr. Arnold received a B.S. in mechanical and aerospace engineering from Princeton University and a Ph.D. in chemical engineering from the University of California, Berkeley.

Caroline Dorsa

Ms. Caroline D. Dorsa is an Independent Director of Illumina, Inc. Ms. Dorsa has held a number of senior management positions at Merck & Co. Inc, including Senior Vice President of Marketing Strategy and Integration, and Vice President and Treasurer, where she also oversaw investor relations, financial planning for manufacturing and tax. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development, and investor relations teams. She is a Director of Biogen Inc. and Intellia Therapeutics, Inc. and a trustee of the Goldman Sachs MLP Income Opportunities Fund and the Goldman Sachs MLP and Energy Renaissance Fund. In addition to her service at Merck & Co. Inc. and at Public Service Enterprise Group, Ms. Dorsa served as Senior Vice President and CFO of Avaya, Inc. She received her B.A. from Colgate University and her M.B.A. from Columbia University.

Karin Eastham

Ms. Karin Eastham, CPA, is an Independent Director of Illumina Inc. since July 2004. Ms. Eastham serves on the boards of directors for several life science companies. From May 2004 to September 2008, she served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of Burnham Institute for Medical Research, a non-profit corporation engaged in basic biomedical research. From 1999 to 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer and Secretary of Diversa Corporation, a biotechnology company. She previously held similar positions with CombiChem, Inc. a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Corporation, a biopharmaceutical company, from 1976 to 1988. Ms. Eastham also serves as a director for MorphoSys AG, a Frankfurt Stock Exchange-listed biotechnology company; Geron Corporation, a NASDAQ-listed biopharmaceutical company; Trius Therapeutics, Inc. a NASDAQ-listed biopharmaceutical company; and Veracyte, Inc. a privately-held molecular diagnostics company. Ms. Eastham also served as a past director of Amylin Pharmaceuticals, Inc. a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Bristol-Myers-Squibb Company in 2012; Genoptix, Inc. a NASDAQ-listed provider of specialized diagnostic laboratory services, from 2008 until its sale to Novartis AG in 2011; Tercica, Inc. a NASDAQ-listed biopharmaceutical company, from 2003 until its sale to Beaufour Ipsen Pharma in 2008; and SGX Pharmaceuticals, Inc., a NASDAQ-listed biopharmaceutical company, from 2005 until its sale to Eli Lilly and Company in 2008. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant.

Robert Epstein

Dr. Robert S. Epstein, M.D. is an Independent Director of Illumina Inc. since November 29, 2012. Dr. Epstein is an epidemiologist who worked in public health and academia before joining the private sector. Prior to this role, Dr. Epstein was Medco’s Chief Medical Officer for 13 years, where he led formulary development, clinical guideline development, drug information services, personalized medicine program development, and client analytics and reporting. Dr. Epstein is also the former President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR), and has served on the board of directors of the Drug Information Association (DIA) and the International Society of Quality of Life. Dr. Epstein serves as a director of AVEO Pharmaceuticals, Inc. a NASDAQ-listed cancer therapeutics company, and Proteus Digital Health, a privately-held healthcare technology company. Dr. Epstein has published more than 75 peer-reviewed medical articles and book chapters and serves as a reviewer for several influential medical journals, including the New England Journal of Medicine and JAMA (The Journal of the American Medical Association). Dr. Epstein received his medical degree and B.S. in Biomedical Science from the University of Michigan and an M.S. in preventative medicine from the University of Maryland. In selecting Dr. Epstein as a past nominee for election to the Board of Directors, the Board considered, among other things, Dr. Epstein’s in-depth experience and practical knowledge of how molecular diagnostic tests are reimbursed and the issues raised by payors and other evidentiary authorities. As our technology and products are increasingly utilized in clinical settings, Dr. Epstein’s experience will contribute to the Board’s understanding of these markets and the risks and opportunities associated with operating in markets regulated by the U.S. Food and Drug Administration.

Gary Guthart

Dr. Gary S. Guthart Ph.D., is an Independent Director of Illumina, Inc, effective December 1, 2017. He joined Intuitive Surgical in April 1996 and has served as the Chief Executive Officer since January 2010. In July 2007, he was promoted to President, having assumed the role of Chief Operating Officer in February 2006. Prior to joining Intuitive Surgical, he was part of the core team developing the foundational technology for computer-enhanced surgery at SRI International (formerly Stanford Research Institute). Dr. Guthart served as a member of the Board of Directors of Affymetrix, Inc. from May 2009 until its acquisition by Thermo Fisher Scientific Inc. in March 2016. Dr. Guthart received a B.S. in Engineering from the University of California, Berkeley and an M.S. and a Ph.D. in Engineering Science from the California Institute of Technology. In selecting Dr. Guthart as a nominee for election to the Board of Directors, the Board considered, among other things, his deep business, operating, financial, and scientific experience as an executive and CEO of a public life sciences company. The Board of Directors believes that Dr. Guthart’s leadership experience as the CEO of a public life sciences and technology company in complex, high growth markets will provide valuable perspective to the Board and the company’s strategic planning and business development efforts.

Philip Schiller

Mr. Philip W. Schiller is an Independent Director of Illumina, Inc. Mr. Schiller is Director of the Company. Schiller has more than 30 years of the marketing and management experience, including over 25 at Apple in various marketing positions; as the Vice President of Product Marketing at Macromedia, Inc. of San Francisco, Calif. as the Director of Product Marketing at FirePower Systems, Inc. of Menlo Park, Calif. as an Information Technology Manager at Nolan, Norton & Company of Lexington, Mass. and as a Programmer and Systems Analyst at Massachusetts General Hospital in Boston. He graduated with a B.S. in biology from Boston College. In selecting Mr. Schiller as a past nominee for election to the Board of Directors, the Board considered, among other things, his track record and global experience in bringing world-class products to market. The Board of Directors believes that Mr. Schiller’s marketing expertise will provide the company and the Board with important insights into communicating the benefits of the company’s products and technology to customers and other stakeholders. Mr. Schiller’s extensive senior management experience in one of the world’s leading consumer technology companies, particularly in key marketing positions, provide the appropriate skills to serve on our Board of Directors.

John Thompson

Mr. John Wendell Thompson is an Independent Director of Illumina, Inc. Mr. Thompson is the Director of the Company, with effect from May 3, 2017. He bringing extensive technology leadership experience to the company. Mr. Thompson’s executive leadership experience includes having served in chief executive officer roles at Symantec and Virtual Instruments, as well as 28 years of prior leadership experience at IBM where he held senior roles in sales, marketing, software development, and as general manager of IBM Americas. He is chairman of the board at Microsoft and has served on the corporate boards of Symantec, NIPSCO (Northern Indiana Public Service Company), Fortune Brands, Seagate Technologies, and United Parcel Service (UPS). Mr. Thompson is a member of the board of trustees for the Wetlands America Trust and formerly a member of the national board of Teach for America. In addition, he has served on several government commissions including the Financial Crisis Inquiry Commission, the National Infrastructure Advisory Council, and the Silicon Valley Blue Ribbon Task Force on Aviation Security and Technology. Mr. Thompson received his B.A. in business administration from Florida A&M University and his M.A. in management science from MIT’s Sloan School of Management. In selecting Mr. Thompson as a nominee for election to the Board of Directors, the Board considered, among other things, Mr. Thompson extensive technology leadership experience, including as a CEO at Symantec and Virtual Instruments and Chairman of the Board at Microsoft. The Board believes his depth and breadth of knowledge in technology, other private sector industries, and the public sector greatly contribute to the Board’s strategic leadership of the Company.

Jacquie Ross

Basic Compensation

Name Fiscal Year Total

Jay Flatley

2,991,900

Francis deSouza

8,807,720

Sam Samad

3,290,350

Garret Hampton

5,922,660

Omead Ostadan

3,453,540

Marc Stapley

3,457,380

Mostafa Ronaghi

3,541,310

Charles Dadswell

1,727,720

Aimee Hoyt

--

Mark Van Oene

3,106,860

Phillip Febbo

--

Frances Arnold

468,102

Caroline Dorsa

1,265,000

Karin Eastham

493,102

Robert Epstein

492,544

Gary Guthart

804,737

Philip Schiller

461,025

John Thompson

846,582

Jacquie Ross

--
As Of  31 Dec 2017